Phase III JADE Compare trial: JAK1 inhibitor abrocitinib treats atopic dermatitis with positive results
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Pfizer Incon Wednesday released a set of data showing that its research JAK1 inhibitor abrocitinib treated adults with moderate to severe asexual dermatitis in phase III JADE Compare trialreached the main endpointThe company said the findings, along with previously reported Phase III JADE MONO-1 and JADE MONO-2 trial data, would support FDA regulatory filingsThe JADE Compare trial recruited 797 patients with moderate to severe asymptomatic dermatitisThe main endpoint is to reach IGA clear or almost clear at week 12, with an eczema area and severity index (EASI75) score of 75% or higher than the baselineThe top line results showed that the percentage of patients who reached the end of the primary therapeutic end at the end of the 12th week was statistically better than placebo, a role Pfizer said lasted until the 16th weekasexual dermatitis is a chronic, itchy, inflammatory skin disease that most commonly occurs in children but also affects many adultsClinical features of asexual dermatitis include dry skin, erythema, oozing and knotting, and moss-like changeItching is a sign of the disease and is a major cause of the burden of illness on patients and their families
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
